IGF1R and breast cancer: Here, we show that IGF-1R blockade results in HR impairment and sensitization to PARP inhibition in ovarian and breast cancer cells without BRCA mutations, providing a rationale to combine IGF-1R and PARP inhibitors in this indication and providing new opportunities for the development of targeted personalized cancer therapy, expanding the number of patients that could benefit from PARP inhibitors.